Use of BIBW 2992, a Novel Irreversible EGFR/HER1 and HER2 Tyrosine Kinase Inhibitor To Treat Patients with HER2-Positive Metastatic Breast Cancer after Failure of Treatment with Trastuzumab
Authors: Hickish, T., Wheatley, D., Lin, N., Carey, L., Houston, S., Mendelson, D., Solca, F., Uttenreuther-Fischer, M., Jones, H. and Winer, E.
Journal: CANCER RESEARCH
Volume: 69
Issue: 24
Pages: 785S
eISSN: 1538-7445
ISSN: 0008-5472
Source: Web of Science (Lite)
Preferred by: Tamas Hickish